SOTIO Biotech

SOTIO Biotech is a private, clinical-stage biotech company headquartered in Prague, Czech Republic, with a strategic presence in the US and Europe. It is developing a diversified pipeline of immunotherapies, including the IL-15 superagonist nanrilkefusp alfa (SOT201) and several ADC candidates (SOT106, SOT109) targeting solid tumors. Backed by the PPF Group, the company leverages proprietary and partnered technology platforms to translate compelling science into patient benefit, with a business model centered on therapeutic development.

Two core platforms: 1) Immunocytokine platform for targeted delivery of cytokine agonists (e.g., IL-15) to the tumor microenvironment. 2) Antibody-Drug Conjugate (ADC) platform utilizing proprietary antibodies and partnered conjugation technologies (e.g., LigaChem's ConjuAll™) to deliver cytotoxic payloads to tumor cells.

SOTIO competes in the crowded but high-growth fields of cytokine therapy (vs. other IL-15 agonists) and ADCs. Differentiation relies on novel targets (LRRC15, CDH17) and proprietary immunocytokine engineering. Success depends on demonstrating superior efficacy/safety in specific solid tumor niches.